EGFR expression in gallbladder carcinoma in North America

International Journal of Medical Sciences

Volumn 5, Issue 5, 2008, Pages 285-291

  Kaufman, Matthew ^a   Mehrotra, Bhoomi ^a   Limaye, Sewanti ^a   White, Sherrie ^b   Fuchs, Alexander ^a   Lebowicz, Yehuda ^a   Nissel Horowitz, Sandy ^a   Thomas, Adrienne ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Differentiation; Endothelial growth factor receptor (EGFR); Gallbladder cancer; Her 2 neu; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GALLBLADDER CARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NORTH AMERICA; PROTEIN EXPRESSION;

EID: 54749094335     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.285     Document Type: Article

References (65)

1. Eckel F and Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer, 2007. 96(6): 896-902.
2. Hezel A.F and Zhu AX. Systemic therapy for biliary tract cancers. Oncologist, 2008. 13(4): 415-23.
3. Iyer R.V, et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol, 2007. 14(11): 3202-9.
4. Riechelmann R.P, et al. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer, 2007. 110(6): 1307-12.
5. Choi C.W, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 2000. 23(4): 425-8.
6. Ducreux M, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol, 1998. 9(6): 653-6.
7. Ellis P.A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer, 1995. 31A(10): 1594-8.
8. Lee M.A, et al. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol, 2004. 130(6): 346-50.
9. Mitry E, et al. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol, 2004. 15(5): 765-9.
10. Glimelius B, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 1996. 7(6): 593-600.
11. Takada T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology, 1994. 51(5): 396-400.
12. Feisthammel J, et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol, 2007. 30(3): 319-24.
13. Burris H.A3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 1997. 15(6): 2403-13.
14. Oettle H, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama, 2007. 297(3): 267-77.
15. Raderer M, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology, 1999. 56(3): 177-80.
16. Gebbia V, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol, 2001. 19(20): 4089-91.
17. Kubicka S, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology, 2001. 48(39): 783-9.
18. Penz M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol, 2001. 12(2): 183-6.
19. Meyerhardt J.A, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci, 2008. 53(2): 564-70.
20. Lee G.W, et al. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol, 2006. 29(2): 127-31.
21. Kim S.T, et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006. 106(6): 1339-46.
22. Andre T, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol, 2004. 15(9): 1339-43.
23. Harder J, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer, 2006. 95(7): 848-52.
24. Wang S.J, et al. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol, 2008. 26(13): 2112-7.
25. Smith G, et al. A 10-year experience in the management of gallbladder cancer. HPB (Oxford), 2003. 5(3): 159-66.
26. Zhou Y.M, et al. [Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. Ai Zheng, 2003. 22(3): 262-5.
27. Ariyama H, et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem, 2006. 97(4): 724-34.
28. Nakazawa K, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol, 2005. 206(3): 356-65.
29. Lee C.S. and A. Pirdas, Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract, 1995. 191(11): 1087-91.
30. Leone F, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res, 2006. 12(6): 1680-5.
31. Manning G, et al. The protein kinase complement of the human genome. Science, 2002. 298(5600): 1912-34.
32. Baselga J and ArteagaCL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol, 2005. 23(11): 2445-59.
33. Macarulla T, et al. Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer, 2006. 6(4): 265-72.
34. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004. 351(4): 337-45.
35. Posner M.R. and L.J. Wirth, Cetuximab and radiotherapy for head and neck cancer. N Engl J Med, 2006. 354(6): 634-6.
36. Nanda R. Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials, 2007. 2(2): 111-6.
37. Metro G, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials, 2006. 1(1): 1-13.
38. Pirker R. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26: 3.
39. Cervantes A. Correlation of KRAS status (wild type [wt] vs mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). Abstract - No 4129 - 2008 ASCO Annual Meeting, 2008.
40. Cutsem EV. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Abstract No 2 - 2008 ASCO Annual Meeting. 2008.
41. Bokemeyer C. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. Abstract No 4000 - 2008 ASCO Annual Meeting, 2008.
42. Paule B, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology, 2007. 72(1-2): 105-10.
43. Sprinzl M.F, et al. Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. BMC Cancer, 2006. 6: 190.
44. Kiguchi K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res, 2001. 61(19): 6971-6.
45. Philip P.A, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol, 2006. 24(19): 3069-74.
46. Lynch T.J, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004. 350(21): 2129-39.
47. Safran H, et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/ oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol, 2008. 31(2): 140-4.
48. Hida Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res, 1999. 19(3B): 2257-60.
49. El Khoueiry AB, et al. A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 2007; 25(suppl 18S): 4639.
50. Nakanuma Y, et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg, 2003. 10(4): 265-81.
51. Lapkus O, et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol, 2006. 19(7): 907-13.
52. Kim H.J, et al. [Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma]. Korean J Gastroenterol, 2005. 45(1): 52-9.
53. Eng C, et al. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol, 2004. 27(6): 565-9.
54. Gupta N, et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol, 2002. 25(1): 96-100.
55. Okusaka T, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol, 2006. 57(5): 647-53.
56. Tsavaris N, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs, 2004. 22(2): 193-8.
57. Gallardo J.O, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol, 2001. 12(10): 1403-6.
58. Park, J.S, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol, 2005. 35(2): 68-73.
59. Doval D.C, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer, 2004. 90(8): 1516-20.
60. Malik I.A, et al. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol, 2003. 26(2): 174-7.
61. Reyes-Vidal J, et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: Results of the phase II Gocchi study. ASCO GI (abstr 87), 2000.
62. Romano R, et al. A combination of cisplatin and irinotecan against advanced biliary tree carcinomas. Journal of Clinical Oncology 2004; 22: 4145.
63. Nehls O, et al. A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas: The final results. Journal of Clinical Oncology, 2006. 24: 4136.
64. Glover KY, et al. A Phase II Study of Oxaliplatin and Capecitabine (XELOX) in Patients with Unresectable Cholangiocarcinoma, including Carcinoma of the Gallbladder and Biliary Tract. Journal of Clinical Oncology, 2005, 23: 4123.
65. Sanz-Altamira P.M, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer, 1998. 82(12): 2321-5.